Orthopedic Biologics Supplier Serving Baton Rouge, LA

Vendor qualification for an orthopedic practice

Orthopedic practices and ambulatory surgery centers generally run new biologics suppliers through a documented review before placing a first order: confirming registration and licensure status, requesting a certificate of analysis for a representative lot, and routing the decision through the practice's medical director. Because Wharton's jelly and exosome products fall under different regulatory frameworks, many practices keep the two product families on separate review tracks rather than approving a single vendor relationship as covering both.

Logistics for shipments into the Gulf South

Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and require -80 degree Celsius storage on arrival; lyophilized formats are shelf-stable and do not need cryogenic handling. Given regional shipping conditions in the Gulf South, practices should plan a receiving workflow that confirms the shipping container's temperature indicator and matches the delivered lot number to its certificate of analysis before the product is logged into inventory.

Documentation and state-level verification

Precision Biologics does not advise on clinical use, dosing, or procedure protocols. Before using any product, practices typically confirm their own license status with the Louisiana State Board of Medical Examiners and consult counsel on whether a specific intended use fits within their regulatory posture. Certificates of analysis, donor eligibility summaries, and lot release records are available to verified accounts to support that internal review.

How account setup works

New accounts are verified using the practice's NPI number against the NPPES registry. Once verified, a Precision Biologics contact can schedule a peer-to-peer call to walk through product documentation, and pricing becomes available. Orders are limited to licensed clinics, physician-supervised medspas, and physicians.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.